TL;DR
Metabolomic signatures of PMOS differ by BMI phenotype; PMOS patients with overweight BMI demonstrate broader metabolomic differences and subsequent implications, while minimal disturbances were noted in lean PMOS patients.
Findings indicate that PCOS and FHA represent fundamentally divergent metabolic states, with obesity acting as a key modifier of metabolic dysfunction in PCOS.
Obesity is strongly associated with a worse metabolic profile in women with PCOS, characterised by marked insulin resistance and dyslipidaemia, while circulating androgen concentrations are broadly comparable across weight categories.
It is suggested that PMOS is not characterized by major gut microbiome shifts but may involve subtle depletion of health-associated commensals and increased microbial heterogeneity.
The presence of exploratory endocrine-metabolic subgroup structure in young women with PCOS is suggested, including a thyroid/autoimmune-enriched subgroup associated with modest differences in lipid-related cardiometabolic risk markers.
Background:Polycystic Ovary Syndrome (PCOS)-recently recognized by medical organizations as Polyendocrine Metabolic Ovarian Syndrome (PMOS)-is a common endocrine disorder affecting women of reproductive age and is frequently associated with obesity, which may aggravate its clinical, metabolic, and hormonal manifestatio...
High-resolution metabolomics identifies a robust, BMI-independent metabolic signature in PCOS characterized by BCAA and energy metabolism alterations, and Selected metabolites show targeted associations with androgen levels, supporting refined metabolic phenotyping in PCOS.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
